Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Restoring immune defenses via lymphotoxin signaling: lessons from cytomegalovirus.

Banks TA, Rickert S, Ware CF.

Immunol Res. 2006;34(3):243-54. Review.

PMID:
16891674
2.

Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection.

Jeitziner SM, Walton SM, Torti N, Oxenius A.

Eur J Immunol. 2013 Nov;43(11):2886-95. doi: 10.1002/eji.201343690. Epub 2013 Aug 26.

3.

Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication.

Kapoor A, Forman M, Arav-Boger R.

PLoS One. 2014 Mar 26;9(3):e92704. doi: 10.1371/journal.pone.0092704. eCollection 2014.

4.

Human cytomegalovirus modulates monocyte-mediated innate immune responses during short-term experimental latency in vitro.

Noriega VM, Haye KK, Kraus TA, Kowalsky SR, Ge Y, Moran TM, Tortorella D.

J Virol. 2014 Aug;88(16):9391-405. doi: 10.1128/JVI.00934-14. Epub 2014 Jun 11.

5.

Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Loewendorf A, Benedict CA.

J Intern Med. 2010 May;267(5):483-501. doi: 10.1111/j.1365-2796.2010.02220.x. Review.

6.

The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity.

Gommerman JL, Browning JL, Ware CF.

Cytokine Growth Factor Rev. 2014 Apr;25(2):139-45. doi: 10.1016/j.cytogfr.2014.02.002. Epub 2014 Mar 12. Review.

7.

Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.

Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.

J Immunol Methods. 2014 Jun;408:101-13. doi: 10.1016/j.jim.2014.05.011. Epub 2014 May 28.

PMID:
24877879
8.
9.

Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells.

Jackson SE, Mason GM, Okecha G, Sissons JG, Wills MR.

J Virol. 2014 Sep;88(18):10894-908. doi: 10.1128/JVI.01477-14. Epub 2014 Jul 9.

10.

[Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].

Kılınçkaya Doğan H, Mutlu E, Köksoy S, Yılmaz VT, Koçak H, Çolak D, Mutlu D, Günseren F, Dinçkan A, Aliosmanoğlu İ, Süleymanlar G, Gültekin M.

Mikrobiyol Bul. 2016 Apr;50(2):224-35. Turkish.

11.

[Cytomegalovirus (CMV)].

Kosugi I.

Uirusu. 2010 Dec;60(2):209-20. Review. Japanese.

12.

Immune responses to congenital cytomegalovirus infection.

Brizić I, Hiršl L, Britt WJ, Krmpotić A, Jonjić S.

Microbes Infect. 2018 Oct - Nov;20(9-10):543-551. doi: 10.1016/j.micinf.2017.12.010. Epub 2017 Dec 26. Review.

PMID:
29287989
13.

Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures.

Rölle A, Olweus J.

APMIS. 2009 May;117(5-6):413-26. doi: 10.1111/j.1600-0463.2009.02449.x. Review.

PMID:
19400865
14.

Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.

Lemmermann NA, Reddehase MJ.

Med Microbiol Immunol. 2016 Dec;205(6):549-561. Epub 2016 Aug 18. Review.

PMID:
27539576
15.

Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells.

Juckem LK, Boehme KW, Feire AL, Compton T.

J Immunol. 2008 Apr 1;180(7):4965-77.

16.

Interplay between CMVs and interferon signaling: implications for pathogenesis and therapeutic intervention.

Trilling M, Le VT, Hengel H.

Future Microbiol. 2012 Nov;7(11):1269-82. doi: 10.2217/fmb.12.109. Review.

PMID:
23075446
17.

Immune-based therapies for cytomegalovirus infection.

Razonable RR.

Immunotherapy. 2010 Jan;2(1):117-30. doi: 10.2217/imt.09.82. Review.

PMID:
20635892
18.

Antigen presentation under the influence of 'immune evasion' proteins and its modulation by interferon-gamma: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells.

Fink A, Lemmermann NA, Gillert-Marien D, Thomas D, Freitag K, Böhm V, Wilhelmi V, Reifenberg K, Reddehase MJ, Holtappels R.

Med Microbiol Immunol. 2012 Nov;201(4):513-25. doi: 10.1007/s00430-012-0256-z. Epub 2012 Sep 9.

PMID:
22961126
19.

Long-distance interferon signaling within the brain blocks virus spread.

van den Pol AN, Ding S, Robek MD.

J Virol. 2014 Apr;88(7):3695-704. doi: 10.1128/JVI.03509-13. Epub 2014 Jan 15.

20.

The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection.

Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA.

Immunol Cell Biol. 2007 Jan;85(1):46-54. Epub 2006 Dec 5. Review.

PMID:
17146464

Supplemental Content

Support Center